EXPERIENCE FAST RDS SUCCESS

 

    Each year, more babies are treated for RDS with CUROSURF® (poractant alfa) Intratracheal Suspension than any other natural surfactant.1

  • Low volume for efficient administration.

    CUROSURF delivers more surfactant in a smaller overall volume for efficient instillation that may help to minimize complications.2-6 Learn More Button

    Clinical studies have not established that lower volume results in superior efficacy or safety based on clinically relevant end points.

  • Rapid onset of action

    CUROSURF goes to work fast, improving oxygenation within 5 minutes.7,8 Learn More Button

    Physiological end points (eg, faster reduction in FiO2) have not been proven to impact key clinical outcomes such as mortality due to RDS.

  • Sustained results with fewer doses

    In clinical studies, most infants required only one dose, which may reduce complications associated with reintubation and subsequent mechanical ventilation.9,13 Learn More Button

    Clinical studies have not established that fewer doses or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

  • Comprehensive support with the CUROSURF Experience Program

    Experience a smooth process evaluating CUROSURF in your NICU with a comprehensive support program from Cornerstone Therapeutics. Learn More Button



Indication

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS)
in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia is recommended prior to CUROSURF administration. Surfactant administration can be expected to reduce the severity of RDS but will not eliminate the mortality and morbidity associated with other complications of prematurity.

Pulmonary Hemorrhage is a known complication of premature birth and very low birth-weight and has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700-2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%), and pulmonary interstitial emphysema (21% vs. 38%).

Please see full prescribing information.

This site is intended for United States residents only.

References: 1. IMS DDD Lung Surfactant Market Purchases May 2004 to December 2011. 2. CUROSURF® (poractant alfa) Intratracheal Suspension Prescribing Information, Cornerstone Therapeutics Inc, April 2010. 3. Survanta® (beractant) Intratracheal Suspension Prescribing Information, Abbott Laboratories, Inc, March 2009. 4. Infasurf® (calfactant) Intratracheal Suspension Prescribing Information, ONY, Inc, June 2011. 5. Gerdes JS, Seiberlich W, Sivieri EM, et al. J Pediatr Pharmacol Ther. 2006;11:92-100. 6. Wiseman LR, Bryson HM. Drugs. 1994;48:386-403. 7. Collaborative European Multicenter Study Group. Pediatrics. 1988;82:683-691. 8. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72:F8-F13. 9. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; And The North American Study Group. Am J Perinatol. 2004;21:109-119. 10. Dizdar EA, Sari FN, Aydemir C, et al. Am J Perinatol. 2012;29(2):95-100. 11. Sandri F, Plavka R, Ancora G, et al. Pediatrics. 2010;125:1402-1409. 12. Dani C, Bertini G, Pezzati M, et al. Pediatrics. 2004;113:e560-e563. 13. Verder H, Albertsen P, Ebbesen F, et al. Pediatrics. 1999;103:1-6.